Lymphoid tyrosine phosphatase (LYP) is often mutated in humans suffering from autoimmune diseases. A recent study proposes a mechanism by which LYP can cause these diseases and suggests that drugs against LYP could be a useful treatment.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Murphy, K., Travers, P., Walport, M. & Janeway, C. Immunobiology, 7th edn. (Garland Science, 2008).
Veillette, A., Rhee, I., Souza, C.M. & Davidson, D. Immunol. Rev. 228, 312–324 (2009).
Cloutier, J.F. & Veillette, A. J. Exp. Med. 189, 111–121 (1999).
Hasegawa, K. et al. Science 303, 685–689 (2004).
Vang, T. et al. Nat. Chem. Biol. 8, 437–446 (2012)10.1038/nchembio.916.
Bottini, N. et al. Nat. Genet. 36, 337–338 (2004).
Vang, T. et al. Nat. Genet. 37, 1317–1319 (2005).
Zhang, J. et al. Nat. Genet. 43, 902–907 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Zhong, MC., Veillette, A. Csk keeps LYP on a leash. Nat Chem Biol 8, 412–413 (2012). https://doi.org/10.1038/nchembio.940
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.940